HeadsafeIP Rights Issue
HeadsafeIP is raising A$2.5 million to provide sufficient runway to the anticipated date of FDA approval and beyond. Shares in this round will be issued at a price of AUD11.06 per share.
To date the company has received commitments of some A$600,000 (US$450,000) from the Houston Group and its investor network (in addition to their advocacy role). We have also received indications of significant support for this raise from our major Australian VCs and shareholders, and from other third parties.
Investors in the company are entitled to pre-emptive rights in this round. You should have received an email with your maximum entitlement. You may subscribe for shares for any amount up to that limit.
Headsafe is revolutionising brain health with the development of the NUROCHEK™ system.
The NUROCHEK system is being developed to leverage cutting-edge technology for fast, portable, and objective assessment of brain function.
Introducing NUROCHEK by Headsafe.
A portable device under development that objectively measures the brain’s normal electrical activity using EEG.